With a few hours to digest this morning鈥檚 oral argument in 黑料正能量 Association v. Becerra, I wanted provide a few high-level reactions.

First, the vast majority of the argument focused on the knotty statutory interpretation questions about whether HHS appropriately exercised its authority to 鈥渃alculate[] and adjust[]鈥 average price as 鈥渘ecessary for purposes of this paragraph.鈥

The Justices were deep in the weeds of the statutory scheme, although at times they鈥攍ike all of us listening at home鈥攁cknowledged just how complex it is. For example, at one point, Justice Kagan humorously remarked: 鈥淩oman ii. I don鈥檛 even know how to do this.鈥 And, at another point, Chief Justice Roberts sounded as if he chuckled (it鈥檚 never easy to tell when merely listening in) when referencing a statutory provision crammed with lowercase letters, capital letters, Roman numerals, and romanettes (鈥淪ection 1395l(t)(14)(A)(iii)(II)鈥).

But the Chief, Justice Kagan, and their colleagues all carefully drilled down on the statute and pressed both advocates about how best to interpret its many interrelated parts. It was refreshing to hear all of the Justices, regardless of ideology or who appointed them, work together to answer a complicated set of legal questions. In fact, there were moments when multiple Justices spoke up at the same time to ask the same question. It definitely seemed as if there was common cause in untangling this uncommonly complicated statutory scheme.

Second, the Court鈥檚 predominant focus on the statutory text and structure is especially noteworthy because of what the Justices focused far less on throughout the argument: (1) the government鈥檚 contention that courts cannot review the kinds of adjustments HHS made here and (2) the broader questions about whether and how to apply Chevron deference.

This is not to say that there was no discussion of Chevron. As noted in the live blog, the very first question of the argument from Justice Thomas was about the continuing viability of Chevron, and some of the final questions of the argument, from Justice Gorsuch, were about how to determine whether a statute is sufficiently ambiguous to invoke the Chevron doctrine.

In addition, Justice Alito directly asked counsel for Petitioners, Don Verrilli, whether Chevron should be overturned if that was the only way he could win his case. (Unsurprisingly, he said yes.) And numerous times during the arguments, the Justices mentioned footnote 9 of Chevron, which says: 鈥淭he judiciary is the final authority on issues of statutory construction and must reject administrative constructions which are contrary to clear congressional intent. . . . If a court, employing traditional tools of statutory construction, ascertains that Congress had an intention on the precise question at issue, that intention is the law and must be given effect.鈥

For those who follow the Court鈥檚 administrative law docket, this was no surprise. This is clearly a Supreme Court that is wrestling with how much deference it owes to administrative agencies as compared to its own role as the ultimate interpreter of federal law.

Third, there is an important connection between these two points that may foretell how this case is ultimately resolved. The usual caveats apply: it is always difficult to predict outcomes based on oral argument.

That said, it did not seem as if the Court believed it needed to 鈥 or was even prepared to 鈥 overrule Chevron in this case, on these facts, with this statute. The tone and tenor of the argument seemed 鈥 at least to me 鈥 to feel as if Chevron will live to fight another day.

Instead, the Court may continue to chip away at the Chevron doctrine as it has repeatedly done in recent years, making it harder for lower courts to reflexively defer to agency interpretations of statutes.

One such case was 2019鈥檚 Kisor v. Wilkie. As Mr. Verrilli pointed out in response to a question by Justice Kavanaugh, the Court explained in Kisor (while citing footnote 9 of Chevron): 鈥淸B]efore concluding that a rule is genuinely ambiguous, a court must exhaust all the 鈥榯raditional tools鈥 of construction.鈥 As Mr. Verrilli put it: 鈥測ou have to exhaust the toolkit.鈥 And although Mr. Verrilli did not mention this particular passage, the Court notably went on in Kisor to state:

That means a court cannot wave the ambiguity flag just because it found the regulation impenetrable on first read. Agency regulations can sometimes make the eyes glaze over. But hard interpretive conundrums, even relating to complex rules, can often be solved.鈥

This may be exactly what we have here: An eye-glazingly complex statute that, with some hard work, nevertheless yields an unambiguous meaning. In the end, the Court may very well agree with Mr. Verrilli鈥檚 final words in his rebuttal: 鈥淗ow much ambiguity is enough? I think the answer is waaaaaaay more than you have here.鈥

If Mr. Verrilli is right, we will now just have to wait a few more months to find how the Court decides to unambiguously interpret the statute.

Chad Golder is an attorney who authored an amicus brief filed by 37 state and regional hospitals associations in support of the AHA鈥檚 arguments in the 340B case. If you missed his live blog during the oral arguments, view it here. The views of the author do not necessarily represent the views of the AHA.

Related News Articles

Headline
Senate Health, Education, Labor, and Pensions Committee Chairman Bill Cassidy, M.D., R-La., today released a report detailing findings from an investigation鈥
Headline
The AHA April 18 filed friend-of-the-court briefs in three cases in support of Louisiana's 340B contract pharmacy law that prohibits drug companies from鈥
Headline
A Minnesota state court April 15 dismissed a lawsuit filed by PhRMA challenging the state鈥檚 law protecting 340B pricing for contract pharmacy arrangements. The鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥
Headline
The Department of Health and Human Services said its decision to prevent drug companies from implementing a 340B rebate model 鈥渨as within its statutory鈥
Headline
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold鈥